OncoMatch/Clinical Trials/NCT06788002
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
Is NCT06788002 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for nasopharyngeal cancinoma (npc).
This study aims to evaluate the efficacy and toxicity of adding low-dose radiotherapy to chemoimmunotherapy as a first-line treatment for nasopharyngeal carcinoma patients with liver metastasis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IVB
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: curative treatment (radical radiotherapy or radical radiotherapy combined with chemotherapy) — curative
patients who had received curative treatment (radical radiotherapy or radical radiotherapy combined with chemotherapy) and developed liver metastasis more than 6 months after treatment completion
Cannot have received: systemic anticancer therapy (including hormone therapy)
Systemic anticancer therapy, including hormone therapy, administered within 28 days prior to the initiation of the study treatment
Cannot have received: immune checkpoint inhibitor (PD-1, PD-L1, CTLA-4)
Previous treatment with immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4)
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1.5 × 10^9/l; platelets ≥ 100 × 10^9/l; hemoglobin ≥ 90 g/l
Kidney function
serum creatinine ≤ 1.5 × uln or estimated glomerular filtration rate (egfr) ≥ 60 ml/min
Liver function
serum total bilirubin ≤ 1.5 × uln (patients with gilbert's syndrome may be included if total bilirubin < 3 × uln); ast and alt ≤ 5 × uln (because of liver metastasis)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify